We are delighted to be able to draw on the experience of our peer-recognised supervisory board, which is comprised of a range of experts with a wealth of valuable experience gained across several industries.

Dr Hubert Birner

Chairman of the Board

Hubert is responsible for overall investment strategy and global fund operations at TVM Capital Life Science, and holds a number of chairmanships in leading life sciences companies. Prior to his current role, he was Head of Business Development Europe and Director of Marketing for Germany at Zeneca Agrochemicals, having joined from McKinsey & Company’s European healthcare and pharmaceutical practice. As a management consultant, he gained extensive experience in R&D management, marketing and sales, and joint venture structuring and business development. Hubert holds a doctoral degree in biochemistry and has an MBA from Harvard Business School.

James C. Gale

The founding partner of Signet Healthcare Partners, James (Jim) has over 30 years of healthcare investing and finance experience. He is a Managing Director in Signet Fund IV and holds a number of board positions across companies in the healthcare sector. Prior to founding Signet, Jim was head of principal investment activities and head of investment banking for Gruntal & Co., where he made a number of investments including Andrx Corporation, Royce Laboratories (merged with Watson Pharmaceuticals), Lifecell Corporation, Neurocrine Biosciences, and BML Pharmaceuticals (acquired by Endo Pharmaceuticals). He holds an MBA from the University of Chicago.

Dr Frank Mathias

Frank has held leadership positions across the pharmaceutical and biotech industry for more than 25 years. He is currently Chief Executive Officer of Rentschler Biopharma SE and also Chairman of vfa bio, which represents the biotech interests within the German Association of Research-Based Pharmaceutical Companies. From 2009 until 2016, Frank was Chief Executive Officer of Medigene AG, having joined the company in 2008 as Chief Operating Officer. Prior to that he worked for Amgen GmbH, Servier Deutschland and Hoechst AG. He is a graduate of Paris VI University, where he studied immunology.

Dr Gerhard Ries

Gerhard has more than 20 years’ experience in global life sciences and venture capital, both as an entrepreneur and investor. Before founding LifeCare Partners, he was co-founder and Managing Partner of BioMedPartners, where he supervised more than 50 investments and served on the board of more than 20 biotech companies. Prior to that, he was co-founder and Managing Director of InterPharmaLink, a specialist portfolio management consulting company for the pharmaceutical industry, and has also held various positions at McKinsey, Novartis, Ciba Geigy and Boehringer Mannheim. Gerhard has a Masters and PhD in Molecular Biology from the University of Basel and a Masters in biotechnology from the Fachhochschule Weihenstephan (Munich).

Enno Spillner

Enno is Chief Financial Officer and a member of the Management Board of Evotec. He previously held the roles of Chairman, CEO and CFO of 4SC AG, having joined the company in September 2005 in the capacity of CEO. Before working for 4SC, Enno was Head of Finance and Controlling at BioM AG, a German regional biotech venture fund, where his responsibilities included finance and controlling as well as managing investments in the equity portfolio. He held the position of Interim Managing Director at two portfolio companies – ACTIPAC Biosystems GmbH and Munich Innovative Biomaterials GmbH – and in 2001, took on the role of Management Partner of BioM VC Fund. Enno earned his Masters in Business from the University of Bamberg, Germany.

Dr Peter Graf

Peter is Investment Manager at the Venture Capital Unit of BayBG, one of the largest mid-cap investment firms in Germany, with a portolio of more than 500 companies and shareholders including, among others, Deutsche Bank, Commerzbank, LfA Förderbank Bayern and Unicredit/Hypovereinsbank. Peter has extensive experience in the IT sector, having founded a Munich- and Berlin-based IT company and delivered successful software projects for clients such as BMW, Diebel’s and Hypovereinsbank. During his time at the Max Planck Institute of Biochemistry, Peter worked on the mechanisms of cell cycle regulation, generating and analysing whole genome data of protein-binding sites and gene-expression data using a combination of wet lab and bioinformatic methods. He holds an degree in Agricultural Sciences and Molecular Biology (with high distinction) and obtained his PhD from LMU Munich.

Dr Robert Becker

Robert has more than 35 years of experience in the pharmaceutical industry. Earlier in his career, he held various leadership positions at Boehringer-Ingelheim, Eli Lilly and Company Biogen Idec and Aptalis. In 2014 he founded Impala Pharma Consulting supporting academic and NGO institutions, Start-up companies, Pharma and Biotech companies from idea generation to launch. He has a strong background in pharmaceutical product development, established a broad vendor network for API, DP and analytical methods development and created strategic partnerships with major collaboration partners for small molecule and protein formulation development. Robert is an expert in process chemistry, design and development of formulations across all pharmaceutical dosage forms and drug delivery systems. Robert is a Chemist by training with focus on Physical Chemistry and holds his Ph.D. from the Technical University Munich, Germany.